Linked Life Data

2511580

Source:http://linkedlifedata.com/resource/pubmed/id/2511580

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1990-1-4
pubmed:abstractText
13 patients with major depressive disorder, who responded well to the reversible MAO-A-inhibitor moclobemide after unsuccessful initial treatment with tri- or tetracyclic antidepressants were monitored under naturalistic outpatient therapy conditions with moclobemide plasma level control for an average of 7.4 months. Due to depressive relapse moclobemide treatment had to be discontinued for 6 patients. Increased dosages or the addition of a tricyclic antidepressant did not bring about any sufficient improvement. The relapse occurred after an average of 2-3 months of treatment with moclobemide administration. In the case of 7 patients it was possible to discontinue treatment with moclobemide after an average of 9.7 months with an incremental reduction in dosage. Recurring depressive symptoms were counteracted in the case of 2 patients by increasing dosages and adding a tricyclic antidepressant. The patients reported good tolerance of the drug as compared to tri- or tetracyclics.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0303-4259
pubmed:author
pubmed:issnType
Print
pubmed:volume
16 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
48-50
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
[Moclobemide in the long-term treatment of depressed patients].
pubmed:affiliation
Psychiatrische Universitätsklinik, Würzburg.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract